These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11829527)

  • 21. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
    Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
    Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.
    Paielli DL; Wing MS; Rogulski KR; Gilbert JD; Kolozsvary A; Kim JH; Hughes J; Schnell M; Thompson T; Freytag SO
    Mol Ther; 2000 Mar; 1(3):263-74. PubMed ID: 10933942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase.
    Oh JY; Park MY; Kim DR; Lee JH; Shim SH; Chung JH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
    Int J Mol Med; 2010 Mar; 25(3):369-76. PubMed ID: 20127041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.
    Lee CT; Lee YJ; Kwon SY; Lee J; Kim KI; Park KH; Kang JH; Yoo CG; Kim YW; Han SK; Chung JK; Shim YS; Curiel DT; Carbone DP
    Cancer Res; 2006 Jan; 66(1):372-7. PubMed ID: 16397251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-specific intravenous gene delivery using oncolytic adenoviruses.
    Zhan J; Gao Y; Wang W; Shen A; Aspelund A; Young M; Laquerre S; Post L; Shen Y
    Cancer Gene Ther; 2005 Jan; 12(1):19-25. PubMed ID: 15514685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes.
    Marienfeld U; Haack A; Thalheimer P; Schneider-Rasp S; Brackmann HH; Poller W
    Gene Ther; 1999 Jun; 6(6):1101-13. PubMed ID: 10455413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the Ad5 upstream E1 region and gene products on heterologous promoters.
    Hoffmann D; Jogler C; Wildner O
    J Gene Med; 2005 Oct; 7(10):1356-66. PubMed ID: 15945123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer.
    Wildner O; Morris JC; Vahanian NN; Ford H; Ramsey WJ; Blaese RM
    Gene Ther; 1999 Jan; 6(1):57-62. PubMed ID: 10341876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
    Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
    Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
    Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
    Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids.
    Yotnda P; Davis AR; Hicks MJ; Templeton NS; Brenner MK
    Mol Ther; 2004 Apr; 9(4):489-95. PubMed ID: 15093179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector.
    Ichikawa T; Chiocca EA
    Cancer Res; 2001 Jul; 61(14):5336-9. PubMed ID: 11454670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy.
    Liu Y; Ye T; Maynard J; Akbulut H; Deisseroth A
    Cancer Gene Ther; 2006 Apr; 13(4):346-56. PubMed ID: 16179927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma.
    Hoffmann D; Heim A; Nettelbeck DM; Steinstraesser L; Wildner O
    Hum Gene Ther; 2007 Jan; 18(1):51-62. PubMed ID: 17184155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
    Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
    Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.
    Haviv YS; Blackwell JL; Kanerva A; Nagi P; Krasnykh V; Dmitriev I; Wang M; Naito S; Lei X; Hemminki A; Carey D; Curiel DT
    Cancer Res; 2002 Aug; 62(15):4273-81. PubMed ID: 12154029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases.
    Sova P; Ren XW; Ni S; Bernt KM; Mi J; Kiviat N; Lieber A
    Mol Ther; 2004 Apr; 9(4):496-509. PubMed ID: 15093180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.